Zymeworks (ZYME) Asset Utilization Ratio (2022 - 2026)
Zymeworks recorded quarterly Asset Utilization Ratio of 0.19 in Q1 2026, down 10.6% quarter-over-quarter from 0.21 in Q4 2025, and up 45.77% year-over-year from 0.13 in Q1 2025.
Zymeworks' Asset Utilization Ratio history runs 5 years deep, the most recent figure standing at 0.19 for Q1 2026.
- In Q1 2026, Asset Utilization Ratio rose 45.77% year-over-year to 0.19; the TTM figure through Mar 2026 stood at 0.19 (up 45.77% YoY), while the FY2025 annual figure was 0.26, up 79.07% from the prior year.
- Asset Utilization Ratio came in at 0.19 for Q1 2026 at Zymeworks, down from 0.21 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.71 in Q4 2022 to a low of 0.09 in Q1 2024.
- A 5-year average of 0.3 and a median of 0.2 in 2025 frame the typical range for Asset Utilization Ratio.
- Across the five-year window, Asset Utilization Ratio plunged 84.93% in 2024 and surged 163.46% in 2025, its largest moves.
- Zymeworks' Asset Utilization Ratio stood at 0.71 in 2022, then tumbled by 81.07% to 0.13 in 2023, then gained by 2.44% to 0.14 in 2024, then soared by 55.8% to 0.21 in 2025, then dropped by 10.6% to 0.19 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.19, 0.21, and 0.27 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | 0.19 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.19 |
| Dec 31, 2025 | 0.21 |
| Sep 30, 2025 | 0.27 |
| Jun 30, 2025 | 0.24 |
| Mar 31, 2025 | 0.13 |
| Dec 31, 2024 | 0.14 |
| Sep 30, 2024 | 0.10 |
| Jun 30, 2024 | 0.10 |
| Mar 31, 2024 | 0.09 |
| Dec 31, 2023 | 0.13 |
| Sep 30, 2023 | 0.66 |
| Jun 30, 2023 | 0.62 |
| Mar 31, 2023 | 0.59 |
| Dec 31, 2022 | 0.71 |